U.S. Launch of Royal Biologics BIOINCYTE PRFM

Royal Biologics commenced U.S. commercial launch of BIOINCYTE PRFM, a next-generation Platelet Rich Plasma (PRP) system. BIOINCYTE converts traditional PRP to Platelet Rich Fibrin Matrix (PRFM) formulations. BIOINCYTE is designed to eliminate extensive contamination of red blood cells and white blood cells during the formulation of PRP.

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us